American management under the control over products and medicines (Food and Drug Administration, FDA) approved the first in the US drug intended for the treatment of postpartum depression. The drug under the trade name Zulresso (active ingredient — brexanolone) is available in a form for intravenous injection.
“Postpartum depression is a serious problem that in severe cases can threaten even life. Women can suffer from obsessive thoughts of harming themselves or their child,” said Tiffany Farquione, acting Director of the FDA’s research center for products related to psychiatric problems.
According to FREE NEWS, only in the United States about 11% of women suffer from postpartum depression. Many of them are forced to use conventional antidepressants now, which may have side effects for them or their baby in case of breastfeeding. “To date, we have not been approved by the FDA antidepressant, which was intended to treat postpartum depression”,— said in an interview with the TV channel Christina Deligiannidis, Director of the center for the study of women’s behavior in the new York clinic Zucker Hillside. It is reported that the drug will be available from June, the course of treatment consists of several injections at a price of about $7.5 thousand Full course of treatment will range from $20 thousand to $35 thousand depending on the severity of the disease and the doctor’s orders.